Receptor-Type Tyrosine-Protein Kinase FLT3 (FLT3) Antibody

This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.

Target	Receptor-Type Tyrosine-Protein Kinase FLT3 (FLT3)
Clonality	Monoclonal
Clone	M049
Reactivity	Human
Tested Applications	ELISA, IHC
Host	Mouse
Recommended dilutions	ELISA: 1/10000, IHC: 1/200 - 1/1000. Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Immunogen	Purified recombinant fragment of human FLT3 (AA: 930-991) expressed in E. coli.
Isotype	IgG1
Form	Liquid
Purification	Purified from ascites by Protein G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
UniProt Primary AC	P36888 (UniProt, ExPASy)
UniProt Secondary AC	A0AVG9, B7ZLT7, B7ZLT8, F5H0A0, Q13414
UniProt Entry Name	FLT3_HUMAN
Gene Symbol	FLT3
GeneID	2322
OMIM	136351
HGNC	3765
KEGG	hsa:2322
Ensembl	ENSG00000122025
String	9606.ENSP00000241453
Molecular Weight	130 kDa
Buffer	PBS, containing 0.05% sodium azide.
Concentration	1 mg/ml
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.

Research Articles on Receptor-Type Tyrosine-Protein Kinase FLT3 (FLT3)

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue